samedan logo
 
 
spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

SMi Presents the 13th Annual Conference: Parallel Trade 2019

SMI Parallel Trade 2019

5-6 February 2019
Holiday Inn Kensington Forum, London

SMi presents its 13th annual Parallel Trade conference, taking place in London on the 5th-6th of February 2019. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

The 2019 event is particularly valuable since Brexit and the news of the UK officially leaving the EU on the 29th of March 2019. As such, the UK will no longer be part of the EU free market; hence, having a significant impact on parallel trade.

Furthermore, the FMD (Falsified Medicines Directive)  will be coming into effect in February 2019. This conference will give companies affected the perfect opportunity to discuss and consider the impact that the FMD implementation will have on their practices and on the market.

EARLY-BIRD RATES:

  • BOOK BY 30TH NOVEMBER AND SAVE 200
  • BOOK BY 14TH DECEMBER AND SAVE 100  
phone +44 (0)20 7827 6000
email events@smi-online.co.uk
web bit.ly/2TsMeab
email London
 
Print this page
Send to a friend
   
spacer
Industry Events

SMi Presents the 13th Annual Conference: Parallel Trade 2019

5-6 February 2019, Holiday Inn Kensington Forum, London

SMi presents its 13th annual Parallel Trade conference, taking place in London on the 5th-6th of February 2019. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.
More info >>

Banner of DIA_Europe_Events_95 on Samedan Banner of Drug Delivery Partnership 2018_events_97 on Samedan

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>


News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement